Roche Diabetes Care has introduced a next-generation predictive continuous glucose monitoring (CGM) solution specifically adapted for the Middle East, where diabetes prevalence ranks among the highest globally. The launch, announced on January 25, 2026, in Dubai, brings together Roche’s advanced sensor hardware with sophisticated AI algorithms that analyse real-time glucose data, historical patterns, meal intake, physical activity, and other contextual factors to predict glucose excursions up to 60 minutes ahead.

The system features:

High-accuracy interstitial glucose sensing with a 14-day wear time

AI-powered predictive alerts for impending hypo- and hyperglycaemia, allowing users to take preventive action

Personalised trend analysis and coaching messages tailored to regional lifestyle factors (e.g., fasting during Ramadan, high-carbohydrate meals, heat-induced dehydration)

Seamless integration with Roche’s mySugr app and compatible insulin pumps for automated adjustments in closed-loop scenarios

Multilingual support (Arabic, English) and offline functionality for areas with limited connectivity

The solution is particularly relevant for the Middle East, where Type 2 diabetes affects over 20% of adults in countries like Saudi Arabia, UAE, and Kuwait. Factors such as sedentary lifestyles, high-sugar diets, irregular meal patterns during Ramadan, and extreme temperatures often lead to unstable glucose control. The predictive AI helps users anticipate and prevent dangerous lows or highs, reducing emergency visits and long-term complications such as retinopathy, neuropathy, and cardiovascular disease.

Dr. Ahmed Al-Mansoori, Regional Medical Director for Roche Diabetes Care in the Middle East, said: “Diabetes management in our region is uniquely challenging due to cultural, dietary, and environmental factors. This predictive CGM solution uses AI to understand individual patterns and provide timely, personalised guidance—empowering people to stay in control and live healthier lives.”

The device has received regulatory clearance in key Middle Eastern markets and is being rolled out through Roche’s network of diabetes clinics, endocrinologists, and hospital partners. Initial real-world evidence from pilot users shows meaningful improvements in time-in-range (TIR), reduced time below range (TBR), and higher user satisfaction due to fewer surprises in glucose levels.

The launch aligns with regional health priorities, including national diabetes strategies in Saudi Arabia (Vision 2030) and the UAE (Weqaya programme), which emphasise prevention, digital tools, and early intervention. Roche plans to expand the solution’s AI capabilities with ongoing model training on Middle East-specific datasets to further refine predictions and recommendations.